反応式
O.[SH2:2].[Na].Cl[C:5]1[C:9]([C:10]2[CH:11]=[N:12][CH:13]=[CH:14][CH:15]=2)=[N:8][S:7][N:6]=1.C(=O)([O-])[O-].[K+].[K+].Br[CH2:23][CH2:24][CH2:25][CH2:26][CH2:27][C:28]#[N:29]>CN(C=O)C.O>[C:28]([CH2:27][CH2:26][CH2:25][CH2:24][CH2:23][S:2][C:5]1[C:9]([C:10]2[CH:11]=[N:12][CH:13]=[CH:14][CH:15]=2)=[N:8][S:7][N:6]=1)#[N:29]参加物
7
実験手順
Sodium hydrogen sulfide monohydrate (0.25 g, 3.3 mmol) was added to a solution of 3-(3-chloro-1,2,5-thiadiazol-4-yl)pyridine (0.59 g, 3.0 mmol) in DMF (20 ml) at room temperature and the reaction mixture was stirred for 1 h. Potassium carbonate (1.24 g, 9 mmol) and 6-bromocapronitrile (0.80 g, 4.5 mmol) were added and the reaction mixture was stirred for additionally 24 h. Water (50 ml) was added and extracted with ether. The combined ether phases were dried and evaporated to give the title compound.
後処理
- stirringthe reaction mixture was stirred for additionally 24 h
- extractionextracted with ether
- dry with materialThe combined ether phases were dried
- customevaporated
出典と根拠
- ORDレコード
- ord-0f8ad05afede4677aa7c477b089d7aa9
- 出典データセット
- uspto-grants-1999_07
- 特許番号
- US05919805
関連ノート
読み込み中…